Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion

Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) has entered the development phase for CCDL24, an innovative treatment for gastrointestinal (GI) disorders. The product utilizes advanced biopolymeric grids from natural ingredients to encapsulate bioactive molecules, enhancing drug efficacy at targeted sites. Current efforts focus on improving physicochemical properties and evaluating gut microflora impact through in vitro studies and simulations.

The global gastrointestinal therapeutics market, valued at $37.6 billion in 2022, is projected to grow at a 3.3% CAGR from 2023 to 2030. This growth is driven by the increasing prevalence of GI disorders and rising demand for effective treatments. CCDL24 builds on the success of CCX0722, leveraging biocompatible hydrogels from natural sources to create biopolymeric matrices for gastrointestinal health.

Positive

• Entering development phase for CCDL24, an innovative GI disorder treatment
• Targeting a market valued at $37.6 billion in 2022
• Leveraging advanced technology to enhance drug efficacy
• Building on the success of previous product CCX0722

Negative

• None.

Insights

Financial Analyst

Cosmos Health's entry into the $37.6 billion gastrointestinal therapeutics market with CCDL24 represents a significant opportunity. The projected 3.3% CAGR until 2030 indicates steady growth potential. However, investors should note that the product is still in the development phase, with no immediate revenue impact. The company's diversified portfolio and vertical integration may provide some risk mitigation, but success in this competitive market is not guaranteed. Key financial considerations include R&D costs, time to market and potential market share capture. While promising, it's too early to quantify the financial impact on Cosmos Health's bottom line.

Medical Research Analyst

CCDL24's innovative approach using biopolymeric grids for targeted drug delivery is noteworthy. The technology's potential to extend bioactive molecule activity at specific sites could significantly enhance treatment efficacy for GI disorders. However, the product is still in early development, with ongoing optimization and in vitro studies. Critical milestones to watch include successful completion of preclinical trials, FDA approval for clinical trials and eventual efficacy data in humans. The growing prevalence of GI disorders presents a substantial market opportunity, but CCDL24 will need to demonstrate superior efficacy or reduced side effects compared to existing treatments to gain significant market share.

Market Research Analyst

The gastrointestinal therapeutics market's size and growth trajectory present a compelling opportunity for Cosmos Health. However, entering a mature market dominated by established players will be challenging. CCDL24's success will hinge on its ability to differentiate itself through superior efficacy, reduced side effects, or cost-effectiveness. Key market factors to monitor include changing treatment paradigms, competitive landscape and potential shifts in healthcare policies. The product's natural ingredient base may appeal to the growing trend of "clean label" medications. Cosmos Health's vertical integration could provide advantages in controlling costs and quality, potentially positioning CCDL24 competitively in this large but crowded market.

CHICAGO, IL / ACCESSWIRE / September 19, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered the development phase for CCDL24, an innovative treatment for gastrointestinal (GI) disorders.

CCDL24 leverages advanced biopolymeric grids derived from natural ingredients to encapsulate bioactive molecules, extending their activity at the targeted site and ultimately enhancing drug efficacy. Current optimization efforts focus on improving its physicochemical properties and evaluating its impact on gut microflora through in vitro studies and simulations.

The figure below illustrates the nano encapsulation technology for CCDL24:

According to Grand View Research, the global gastrointestinal therapeutics market was valued at $37.6 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 3.3% from 2023 to 2030. The market growth is primarily driven by the increasing prevalence of gastrointestinal disorders such as IBS, Crohn's disease, and ulcerative colitis, along with the rising demand for effective gastrointestinal treatments.

Greg Siokas, CEO of Cosmos Health, stated: "Building on the success of CCX0722, which features biocompatible hydrogels from natural sources, Cosmos has applied this cutting-edge technology to develop a new series of biopolymeric matrices specifically designed to address gastrointestinal health."

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653

SOURCE: Cosmos Health Inc.

View the original press release on accesswire.com

FAQ

What is CCDL24 and what is it designed to treat?

CCDL24 is an innovative treatment developed by Cosmos Health (NASDAQ:COSM) designed to treat gastrointestinal (GI) disorders. It uses advanced biopolymeric grids from natural ingredients to encapsulate bioactive molecules, enhancing drug efficacy at targeted sites.

What is the projected growth of the gastrointestinal therapeutics market that CCDL24 is targeting?

The global gastrointestinal therapeutics market, which CCDL24 is targeting, was valued at $37.6 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 3.3% from 2023 to 2030.

How does CCDL24 relate to Cosmos Health's previous product CCX0722?

CCDL24 builds on the success of CCX0722, which features biocompatible hydrogels from natural sources. Cosmos Health has applied this technology to develop CCDL24, a new series of biopolymeric matrices specifically designed for gastrointestinal health.

What is the current development stage of CCDL24 by Cosmos Health (NASDAQ:COSM)?

Cosmos Health (NASDAQ:COSM) has entered the development phase for CCDL24. Current efforts are focused on optimizing its physicochemical properties and evaluating its impact on gut microflora through in vitro studies and simulations.